Last $5.76 USD
Change Today -0.11 / -1.87%
Volume 60.5K
ALIM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

alimera sciences inc (ALIM) Snapshot

Open
$5.87
Previous Close
$5.87
Day High
$5.92
Day Low
$5.73
52 Week High
01/17/14 - $8.44
52 Week Low
10/18/13 - $1.65
Market Cap
232.3M
Average Volume 10 Days
82.2K
EPS TTM
$-1.15
Shares Outstanding
40.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALIMERA SCIENCES INC (ALIM)

alimera sciences inc (ALIM) Related Businessweek News

No Related Businessweek News Found

alimera sciences inc (ALIM) Details

Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

31 Employees
Last Reported Date: 03/7/14
Founded in 2003

alimera sciences inc (ALIM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $505.7K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $352.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $333.4K
Compensation as of Fiscal Year 2013.

alimera sciences inc (ALIM) Key Developments

Alimera Sciences, Inc.'s ILUVIEN(R) Receives Positive Outcome of Repeat-Use Procedure for 10 Additional European Countries

Alimera Sciences, Inc. announced the positive outcome of the Repeat-Use Procedure for ILUVIEN(R) for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries. Alimera submitted the application through the Mutual Recognition Procedure (MRP) with the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) serving as the Reference Member State. The regulatory process for these additional countries, consisting of Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic, will now enter the national phase in which each country grants marketing authorization. ILUVIEN will be indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.

Alimera Sciences, Inc. - Shareholder/Analyst Call

Annual Stockholders Meeting

Alimera Sciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 01:30 PM

Alimera Sciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 01:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Charles Daniel Myers, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIM:US $5.76 USD -0.11

ALIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALIM.
View Industry Companies
 

Industry Analysis

ALIM

Industry Average

Valuation ALIM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALIMERA SCIENCES INC, please visit www.alimerasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.